Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.10 USD
+0.90 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum C VGM
Zacks News
Boston Scientific's (BSX) New Buyout to Expand Global Presence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.
Perrigo (PRGO) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PETQ or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
by Zacks Equity Research
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
Boston Scientific (BSX) Posts Positive Post-Market Study Data
by Zacks Equity Research
The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.
Why Is Boston Scientific (BSX) Up 5.6% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PETQ or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Comcast, Intuit, Boston Scientific, Freeport-McMoRan and Autodesk
by Zacks Equity Research
Comcast, Intuit, Boston Scientific, Freeport-McMoRan and Autodesk are included in this Analyst Blog.
Top Research Reports for Comcast, Intuit & Boston Scientific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Intuit Inc. (INTU) and Boston Scientific Corporation (BSX).
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
Boston Scientific (BSX) Lags Q3 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -2.27% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Intuit, Diageo, Sony Group, Southern, and Boston Scientific
by Zacks Equity Research
Intuit, Diageo, Sony Group, Southern, and Boston Scientific are included in this Analyst Blog.
Top Research Reports for Intuit, Diageo & Sony
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Intuit Inc. (INTU), Diageo plc (DEO) and Sony Group Corp. (SONY).
Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
by Zacks Equity Research
Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
Why Boston Scientific (BSX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
by Zacks Equity Research
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
by Zacks Equity Research
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
General Electric (GE), Boston Scientific Bond Over Heartcare
by Zacks Equity Research
General Electric's (GE) partnership deal will help the cardiac patients easily avail of heart care treatment.
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
by Zacks Equity Research
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.